Results 101 to 110 of about 186,499 (128)
Some of the next articles are maybe not open access.
Cerliponase Alfa for CLN2 Disease, a Promising Therapy
Expert Opinion on Orphan Drugs, 2020Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare, lysosomal storage disease that causes progressive neurodegeneration in children.
Nicolas J Abreu, Jonathan Pindrik
exaly +2 more sources
Neuronal Ceroid Lipofuscinosis type 2 (CLN2) is a neurodegenerative lysosomal disease which leads to early dementia and death without treatment. The recently available therapy consists of intracerebroventricular enzyme substitution: cerliponase alfa. In this report, we describe the evolution of the first French children treated with cerliponase alfa ...
Stéphane Auvin +2 more
exaly +3 more sources
Safety and Efficacy of Cerliponase Alfa in Children With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2 Disease): An Open-Label Extension Study [PDF]
Background: Cerliponase alfa is a recombinant human tripeptidyl peptidase 1 (TPP1) enzyme replacement therapy for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), which is caused by mutations in the TPP1 gene.
Anupam Chakrapani +2 more
exaly +2 more sources
Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics [PDF]
Neuronal ceroid lipofuscinosis type 2 or CLN2 disease is a rare, autosomal recessive, neurodegenerative lysosomal storage disorder caused by tripeptidyl peptidase 1 deficiency. Cerliponase alfa, a recombinant human tripeptidyl peptidase 1 enzyme, is the first and only approved treatment for CLN2 disease and the first approved enzyme replacement therapy
Raymond Y Wang +2 more
exaly +3 more sources
Anita Datta, Sylvia Stockler-Ipsiroglu
exaly +3 more sources
Cerliponase Alfa for Pediatric Patients With Neuronal Ceroid Lipofuscinosis Type 2 Disease
Canadian Journal of Health TechnologiesWhat Is the Issue? Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is an ultrarare, severe, and rapidly progressing lysosomal storage disorder, with a global incidence of approximately 0.15 to 9.0 per 100,000 live births. It has a devastating impact on children and families, leading to rapid functional decline and early death without effective ...
openaire +1 more source
Erratum. A survival analysis of ventricular access devices for delivery of cerliponase alfa
Journal of Neurosurgery: Pediatrics, 2022openaire +2 more sources
Journal of Neurosurgery: Pediatrics
OBJECTIVE Cerliponase alfa is an enzyme replacement treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), administered via biweekly intracerebroventricular infusions. Typically, infusions are delivered via a head-sited access device; however, subcutaneously tunneled chest-sited devices could offer an ...
Jack, Read +10 more
openaire +2 more sources
OBJECTIVE Cerliponase alfa is an enzyme replacement treatment for neuronal ceroid lipofuscinosis type 2 (CLN2), administered via biweekly intracerebroventricular infusions. Typically, infusions are delivered via a head-sited access device; however, subcutaneously tunneled chest-sited devices could offer an ...
Jack, Read +10 more
openaire +2 more sources

